Clinical trials: Atrophic Gastritis
Chronic Atrophic Gastritis, Hypergastrinaemia
YF476 and Type I Gastric Carcinoids
The aim of the study is to find out if the experimental medicine, YF476, can make gastric carcinoids, a rare type of stomach tumour, shrink and disappear.
- Conditions
- Chronic Atrophic Gastritis, Hypergastrinaemia, Type I Gastric Carcinoids
- Trial name
- NCT01339169
- Testing
- YF476
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Trio Medicines Ltd.
Gastritis, Atrophic, Stomach Neoplasms
Gastropanel for Gastric Atrophy and Cancer Risk Assessment
Background: Atrophic gastritis (AG) is the single most important precursor condition for gastric cancer (GC) known so far. H. pylori infection is the most important causative agent of gastritis, and subsequent AG.
- Trial name
- NCT02114411
- Testing
- GastroPanel test, Gastroscopy
- Where
- United Kingdom
- Volunteers
- 250 people
- Sponsor
- Biohit Healthcare Ltd
Chronic Atrophic Gastritis (CAG)
To Evaluate the Efficacy and Safety of Vitamin B12 Contains Extract of Lamb's Stomach in Treatment of Chronic Atrophic Gastritis (CAG)
The purpose of this study is to determine whether Gastropyloric Complex Capsules are safe and effective in the treatment of chronic atrophic gastritis (CAG).
- Trial name
- NCT01474044
- Testing
- Gastropylor Complex Capsules
- Where
- China
- Volunteers
- 851 people
- Sponsor
- Xinjiang Biochemical Pharmaceutical Co., Ltd.
Chronic Atrophic Gastritis, Hypergastrinemia
YF476 and Type I Gastric Carcinoids (Norway)
The aim of the study is to find out if the experimental medicine, YF476, can make gastric carcinoids, a rare type of stomach tumour, shrink and disappear.
- Conditions
- Chronic Atrophic Gastritis, Hypergastrinemia, Type I Gastric Carcinoids
- Trial name
- NCT01444014
- Testing
- YF476
- Where
- Norway
- Volunteers
- 8 people
- Sponsor
- Trio Medicines Ltd.